Evidence-Based Therapy May Improve Outcome in Glomerulonephritis—A Prospective Field Survey

Abstract Full-Text HTML Download Download as PDF (Size:460KB) PP. 49-59
DOI: 10.4236/ojneph.2012.24009    3,458 Downloads   5,956 Views   Citations

ABSTRACT

Introduction and aims: Although glomerulonephritis is rare in the general population it is the second most important cause for end-stage renal failure. The therapy of glomerulonephritis is guided by a limited number of individual clinical trials and treatment recommendations are based on meta-analysis and Cochrane Systematic Reviews. The impact of such therapy standards on the prognosis of glomerulonephritis is not known. Methods: Between October 2002 and December 2008 patients with abnormal urine findings and/or decreasing renal function of unknown cause were referred for renal biopsy. In a collaboration of out-patient nephrologists with a major teaching hospital, all patients received treatment recommendations according to evidence-based therapy guidelines based on Cochrane Systematic Reviews. Patient charts were systematically reviewed and patients were re-examined for follow-up until November 2009. Cox Regression analysis was performed to identify independent prognostic factors. Results: Two hundred patients with primary or secondary glomerulonephritis were identified. Complete follow-up data were available from 196 patients with 324 therapeutic interventions. The mean follow-up was 2.8 ± 2.0 years. Among all patients, 37% remained unchanged ill, 13% died, 17% had progressing renal disease, while 19% had a complete and 14% a partial remission. Proteinuria declined in primary glomerulonephritis (5.0 ± 5.4 g/d to 2.1 ± 3.4 g/d, p < 0.001) and secondary glomerulonephritis (4.8 ± 4.6 g/d to 2.7 ± 3.1 g/d, p = 0.004). The highest rates of remission were observed in minimal change disease (83%) and membranous nephropathy (50%). Survival was lowest in MPGN and secondary rapid-progressive glomerulonephritis (33% and 50%, respectively). 70 (22%) interventions were complicated by adverse events resulting in treatment cessation in 25 cases. Cox univariate analyses identified the following parameters to improve outcome: Histology, no tubulointerstitial fibrosis, primary glomerulopathy, absence of hypertension at presentation, diabetes, ischemic heart disease, no diuretics or insulin, serum creatinine < 175 μmol/l, blood pressure < 160 mmHg, age < 60 ys, prednisolone, cyclosporin A, azathioprine, and follow-up by 24 hr urine. In a multivariate forward Cox regression analysis, tubulo-interstitial fibrosis had a hazard for the combined end-point of death, dialysis and progression of renal failure of 4.4 (95% confidence interval (95% CI: 1.8 - 10.6) while intensive follow-up by regular 24 hr urine collections reduced the risk to 0.3 (95% CI: 0.1 - 0.7), treatment with prednisolone had a hazard of 0.3 (95% CI: 0.1 - 0.9), and cyclosporin A therapy a hazard of 0.2 (95% CI: 0.02 - 1.4). Application of Cochrane review based therapy guidelines along with intensified monitoring of renal function prolonged dialysis-free survival by 1.7 years. Conclusions: In a multivariate model of standardised glomerulonephritis therapy the presence of tubulointerstitial fibrosis was associated with death or progresssive renal disease, while prednisolone-based therapy regimens and intensified nephrological follow-up resulted in a significant delay of endstage-renal failure. This result should direct future health care policies because glomerulonephritis accounts for nearly 20% of the dialysis population.

Cite this paper

N. Braun, A. Schweisfurth, H. Gröne and G. Kundt, "Evidence-Based Therapy May Improve Outcome in Glomerulonephritis—A Prospective Field Survey," Open Journal of Nephrology, Vol. 2 No. 4, 2012, pp. 49-59. doi: 10.4236/ojneph.2012.24009.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] N. Braun, A. Schweisfurth, C. Lohofener, et al., “Epidemiology of Glomerulonephritis in Northern Germany,” International Urology and Nephrology, Vol. 43, No. 4, 2011, pp. 1117-1126. doi:10.1007/s11255-011-9955-4
[2] Council of the European Union, “Council Recommendation on an Action in the Field of Rare Diseases,” Interinstitutional File 2008/0218 (CNS).
[3] U. Frei and H.-J. Schober-Halstenberg, “Nierenersatztherapie in Deutschland 2006/2007,” Quasi-Niere gGmbH, Sch?neberg, 2008.
[4] K. Farrington, A. Hodsman, A. Casula, D. Ansell and J. Feehally, “UK Renal Registry 11th Annual Report (December 2008): Chapter 4 ESRD Prevalent Rates in 2007 in the UK: National and Centre-Specific Analyses,” Nephron Clinical Practice, Vol. 111, Suppl. 1, 2009, pp. c43-c68
[5] S. C. Chen, “United States Renal Data System—the concise 2008 annual data report,” 2008. www.usrds.org.
[6] A. Rüther, H. P. Dauben and H. Schweim, “Die Deutsche Agentur für Health Technology Assessment (HTA) Beim DIMDI (DAHTA@DIMDI),” Bundesgesundheitsbl-Ge- sundheitsforsch-Gesundheitsschutz, Vol. 44, No. 9, 2001, pp. 865-869.
[7] S. C. Palmer, K. Nand and G. F. Strippoli, “Interventions for Minimal Change Disease in Adults with Nephrotic Syndrome,” Cochrane Database of Systematic Reviews, Vol. 23, No. 1, D001537.
[8] C.-K. Yeung, K.-L. Wong and W. L. Ng, “Intravenous Methylprednisolone Pulse Therapy in Minimal Change Nephrotic Syndrome,” Australian and New Zealand Jour- nal of Medicine, Vol. 13, No. 4, pp. 349-351. doi:10.1111/j.1445-5994.1983.tb04479.x
[9] E. M. Hodson, N. S. Willis and J. C. Craig, “Corticosteroid Therapy for Nephrotic Syndrome in Children,” Cochrane Database of Systematic Reviews, No. 4, 2007, CD001533.
[10] E. M. Hodson, D. Habashy and J. C. Craig, “Interventions for Idiopathic Steroid-Resistant Nephrotic Syndrome in Children,” Cochrane Database of Systematic Reviews, Vol. 19, No. 2, 2006, CD003594
[11] E. M. Hodson, N. S. Willis and J. C. Craig, “Non-Corticosteroid Treatment for Nephrotic Syndrome In Children,” Cochrane Database of Systematic Reviews, No. 4, 2008, CD002290
[12] N. Braun, F. Schmutzler, C. Lange, et al., “Immunosuppressive Treatment for Focal Segmental Glomerulosclerosis in Adults (Review), Non-Corticosteroid Treatment for Nephrotic Syndrome in Children,” Cochrane Database of Systematic Reviews, No. 3, 2008, CD003233.
[13] G. Banfi, M. Moriggi, E. Sabadini, G. Fellin, G. D’Amico and C. Ponticelli, “The Impact of Prolonged Immunosup- pression on the Outcome of Idiopathic Focal-Segmental Glomerulosclerosis with Nephrotic Syndrome in Adults. A Collaborative Retrospective Study,” Clinical Nephrology, Vol. 36, No. 2, 1991, pp. 53-59.
[14] J. A. Samuels, G. F. Strippoli, J. C. Craig, F. P. Schena and D. A. Molony, “Immunosuppressive Agents for Treating IgA Nephropathy,” Cochrane Database of Systematic Reviews, No. 4, 2003, CD003965.
[15] J. Floege and H. J. Grone, “IgA-Nephropathie,” Der Internist, Vol. 44, No. 9, 2002, pp. 1131-1139. doi:10.1007/s00108-003-1026-1
[16] C. Pozzi, P. G. Bolasco, G. B. Fogazzi, et al., “Corticosteroids in IgA Nephropathy: A Randomised Controlled Trial,” Lancet, Vol. 353, No. 9156, 1999, pp. 883-887. doi:10.1016/S0140-6736(98)03563-6
[17] F. W. Ballardie and I. S. D. Roberts, “Controlled Prospective Trial of Prednisolone and Cytotoxis in Progressive IgA Nephropathy,” Journal of the American Society of Nephrology, Vol. 13, No. 1, 2002, pp. 42-148.
[18] A. Schieppati, A. Perna, J. Zamora, G. A. Giuliano, N. Braun and G. Remuzzi, “Immunosuppressive Treatment for Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome,” Cochrane Database of Systematic Reviews, No. 4, 2004, CD004293.
[19] D. Cattran, “Management of Membranous Nephropathy: When and What for Treatment,” Journal of the American Society of Nephrology, Vol. 16, No. 5, 2005, pp. 1188-1194. doi:10.1681/ASN.2005010028
[20] C. Ponticelli, P. Altieri, F. Scolari, et al., “A Randomized Study Comparing Methylprednisolone Plus Chlorambucil versus Methylprednisolone Plus Cyclophosphamide in Idiopathic Membranous Nephropathy,” Journal of the American Society of Nephrology, Vol. 9, No. 3, 1998, pp. 444-450.
[21] G. Walters, N. S. Willis and J. C. Craig, “Interventions for Renal Vasculitis in Adults,” Cochrane Database of Systematic Reviews, No. 3, 2008, CD003232.
[22] American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines, “Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults,” Arthritis & Rheumatism, Vol. 42, 1999, pp. 1785-1796.
[23] R. S. Flanc, M. A. Roberts, G. F. Strippoli, S. J. Chadban, P. G. Kerr and R. C. Atkins, “Treatment for Lupus Nephritis,” Cochrane Database of Systematic Reviews, No. 1, 2004, CD002922.
[24] C. S. Wilcox, “New Insights into Diuretic Use in Patients with Chronic Renal Disease,” Journal of the American Society of Nephrology, Vol. 13, No. 2002, pp. 798-805.
[25] G. Maschio, D. Alberti, F. Locatelli, et al., “Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group,” Journal of Cardiovascular Pharmacology, Vol. 33, Suppl. 1, 1999, pp. S16-S20. doi:10.1097/00005344-199900001-00004
[26] D. Cox, “Regression Models and Life Tables,” Journal of the Royal Statistical Society. Series B, Vol. 34, No. 2, 1972, pp. 187-220.
[27] R. Muecke, O. Micke, B. Reichl, et al., “Demographic, Clinical and Treatment Related Predictors for Event-Free Probability Following Low-Dose Radiotherapy for Painful Heel Spurs—A Retrospective Multicenter Study of 502 Patients,” Acta Oncologica, Vol. 46, No. 2, 2007, pp. 239-246. doi:10.1080/02841860600731935
[28] D. L. Sackett, S. E. Straus, W. S. Richardson, W. Rosenberg and R. B. Haynes, “Evidence-Based Medicine: How to Practic and Teach EBM,” Churchill Livingstone, Edinburgh, 2000.
[29] A. Bohle, S. Mackensen-Haen and G. H. Von, “Signifi- cance of Tubulointerstitial Changes in the Renal Cortex for the Excretory Function and Concentration Ability of the Kidney: A Morphometric Contribution,” American Journal of Nephrology, Vol. 7, No. 6, 1987, pp. 421-433. doi:10.1159/000167514
[30] D. C. Cattran, R. Coppo, H. T. Cook, et al., “The Oxford Classification of IgA Nephropathy: Rationale, Clinicopathological Correlations, and Classification,” Kidney International, Vol. 76, No. 5, 2009, pp. 534-545. doi:10.1038/ki.2009.243
[31] “Safety and Tolerability of Cyclosporin a (Sandimmun) in Idiopathic Nephrotic Syndrome. Collaborative Study Group of Sandimmun in Nephrotic Syndrome,” Clinical Nephrology, Vol. 35, Suppl. 1, 1991, pp. S48-S60
[32] D. C. Cattran, G. B. Appel, L. A. Hebert, et al., “A Randomized Trial of Cyclosporine in Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis. North America Nephrotic Syndrome Study Group,” Kidney International, Vol. 56, 1999, pp. 2220-2226. doi:10.1046/j.1523-1755.1999.00778.x
[33] E. Imbasciati, R. Gusmano, A. Edefonti, et al., “Controlled Trial of Methylprednisolone Pulses and Low Dose Oral Prednisone for the Minimal Change Nephrotic Syndrome,” British Medical Journal (Clinical Research Ed.), Vol. 291, No. 6505, 1985, pp. 1305-1308. doi:10.1136/bmj.291.6505.1305
[34] D. J. Wallace, D. Goldfinger, G. Savage, et al., “Predictive Value of Clinical, Laboratory, Pathologic, and Treatment Variables in Steroid/Immunosuppressive Resistant Lupus Nephritis,” Journal of Clinical Apheresis, Vol. 4, No. 1, 1988, pp. 30-34. doi:10.1002/jca.2920040107
[35] D. R. Jayne, G. Gaskin, N. Rasmussen, et al., “Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis,” Journal of the American Society of Nephrology, Vol. 18, No. 7, 2007, pp. 2180-2188. doi:10.1681/ASN.2007010090
[36] NKF K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease,” American Journal of Kidney Diseases, Vol. 43, Suppl. 291, 2004, pp. S1-S290. doi:10.1053/S0272-6386(04)00369-5

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.